# rCSP/AP10-602 [GLA-LSQ] Vaccine Trial

> **NCT03589794** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 65 (actual)

## Conditions studied

- Plasmodium Falciparum Infection

## Interventions

- **OTHER:** AP10-602
- **OTHER:** Malaria challenge
- **BIOLOGICAL:** rCSP

## Key facts

- **NCT ID:** NCT03589794
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589794, "rCSP/AP10-602 [GLA-LSQ] Vaccine Trial". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03589794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*